Rediscovery of metformin for the chronic disabling auto-inflammatory disease hidradenitis suppurativa

Phase 3

Recruiting

• Conditions: Acne inversa; Verneuil's disease; 10040798

• Registration Number: NL-OMON50983
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 62

Inclusion Criteria

• Age >=18 years at baseline
• A diagnosis of HS for at least 1 year prior to baseline
• mild to moderately active disease defined by a HS Physician Global Assessment
(HS-PGA)
score of 2-3 and the Refined Hurley classification of mild to moderate
at baseline
• Indication for systemic therapy; i.e. uncontrolled disease under conventional
topical therapy.
• Able and willing to give written informed consent and to comply with the
study requirements.

Exclusion Criteria

• Pregnant and lactating women
• Previously diagnosed diabetes mellitus and receiving active treatment
• Use of oral antibiotics within 14 days prior to baseline
• Use of immunosuppressing/modulating therapies within 28 days prior to baseline
• A known allergy to metformin or doxycycline or any of the ingredients
metformin or doxycycline
• Contraindications for the use of either metformin (e.g. acute metabolic
acidosis, or severe
kidney failure with a creatinine clearance < 30 ml/min) or doxycycline
(severe liver function
disorders)

Study & Design

• Study Type: Interventional
• Study Design: Not specified